Bevacizumab, a humanized monoclonal antibody to VEGF, is FDA approved in combination with chemotherapy for treatment of advanced non-small cell lung cancer (NSCLC) and several small molecule tyrosine kinase inhibitors, including, Sunitinib, Cediranib and Vatalanib, are currently being investigated in NSCLC clinical trials [4]. The gene discussed is VEGFA; the disease is non-small cell lung carcinoma.